Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner - Wikidata - wikimedia - TriplyDB

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

http://www.wikidata.org/entity/Q36016318

about

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside Smart nanosystems: Bio-inspired technologies that interact with the host environment Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.Fibroblast Growth Factor 9 Imparts Hierarchy and Vasoreactivity to the Microcirculation of Renal Tumors and Suppresses Metastases Exploring the tumor microenvironment with nanoparticles Evaluation of uptake and distribution of gold nanoparticles in solid tumors Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp Intravital Microscopy Imaging Approaches for Image-Guided Drug Delivery Systems 3D Imaging of Nanoparticle Distribution in Biological Tissue by Laser-Induced Breakdown Spectroscopy Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches Enhancing Tumor Penetration of Nanomedicines.Sonoporation enhances liposome accumulation and penetration in tumors with low EPR.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Interstitial fluid flow in cancer: implications for disease progression and treatment.Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution.Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Modeling of nanotherapeutics delivery based on tumor perfusion.Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.Intravital imaging of mouse colonic adenoma using MMP-based molecular probes with multi-channel fluorescence endoscopy Measuring Vascular Permeability In Vivo Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells The role of mechanical forces in tumor growth and therapy Strategies for advancing cancer nanomedicine.Cellular and physiological roles for phospholipase D1 in cancer.Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction.Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model A smart and versatile theranostic nanomedicine platform based on nanoporphyrin.Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan

P2860

Q24627664-0348B4EE-B63E-4AF7-831A-24CE67BD8859 Q26746067-9A6144ED-5EAB-48C6-A0FB-895578016798 Q26770678-A55FE2AF-7172-44AD-919D-E99400E0DA82 Q26776370-D6A2BE49-1F6C-49B8-9F5F-F823B7A7A93D Q26777144-8D253A89-352B-4B26-AAE6-92F1433CC672 Q26796955-D6D1A806-88A7-4C05-BCBD-72BBC2720415 Q26799981-F04A8BA7-1220-42D5-B7DF-D8A2E08DD641 Q26828930-BEEA746D-1753-406C-86F3-6ACA6FBB74EA Q26999332-EB8117B2-6A99-465C-BE18-50BED3EC257A Q27002209-FD4DBC19-2210-464B-8FE8-ECC87F841B01 Q27312628-C783730A-889C-4654-95FD-E29BDCC25C67 Q28082374-74483C26-5474-440D-A186-503E17B4E083 Q28390095-4755E372-2CC9-46A5-80D9-7F49E38F0704 Q28546603-5D86D600-2E58-4A7F-888A-B75ADF50D991 Q28553638-0FE75318-2F3D-4AFA-B6E6-8750B93FD4F0 Q28596080-A909B98C-5A6F-4FF6-8278-401D2F970222 Q30354223-07813CC1-FB74-4D76-A6C7-9484E8502E49 Q30356887-3336E98A-5131-4188-8B2F-3E48AA0FDB1D Q30358121-EB5907D6-BB44-49A4-B885-F1B0668761C5 Q30399006-34EE1DE0-4C60-41E5-8827-7493F6588963 Q30411142-51144969-F645-49D1-BDCE-A2364AD0753C Q30413615-08CDC62C-7FE1-43FB-9BFC-3346F40CF704 Q30525290-1E35D1B4-221E-403C-9860-21C8AD866BAA Q30542073-C8BADFD1-F601-4E2E-934B-C4C9A2D9D7E0 Q30544603-B96F3A6E-A13B-46CE-91DB-83BC54C4D5B0 Q30581724-53BA5D69-D22C-462E-93A9-1B5C84DE778F Q30651792-8958B2D2-028A-4CEB-9A10-CCA950CED826 Q31144268-F1DA0E80-46D4-48AC-BA56-125498566FC0 Q33441574-42DD4EB8-8D94-45AA-A06A-31A44BAA2A17 Q33634587-D605DA22-1493-409F-8654-DE594146BDEC Q33699854-00C3ECA8-1998-4F78-A85C-194596AAADF0 Q33773319-BB5FD357-73C7-4144-87F1-FB07E1BB129D Q33824874-47F0DAEA-49D1-4907-BC90-BD8D989E91AC Q33942378-47049273-94DD-4C12-B6A4-4A2AED854DF6 Q33995719-ED2211CA-B8DB-450C-A9DF-8DE406B61240 Q34044529-8CAA8E46-5EFB-4953-9FF9-056594A9F43B Q34061502-33E97206-E856-4576-A087-16A4EC7C1753 Q34092162-704EA302-2C62-4057-B77B-BA76423B63E1 Q34093247-1EE040B3-9D6F-4F80-8B79-DEB0AC637638 Q34145464-F5A8F379-41B6-4FE9-99E4-B1064EBEE9EF

P2860

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

http://www.wikidata.org/entity/Q36016318

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Normalization of tumour blood ...... nes in a size-dependent manner

@ast

Normalization of tumour blood ...... nes in a size-dependent manner

@en

type

label

Normalization of tumour blood ...... nes in a size-dependent manner

@ast

Normalization of tumour blood ...... nes in a size-dependent manner

@en

prefLabel

Normalization of tumour blood ...... nes in a size-dependent manner

@ast

Normalization of tumour blood ...... nes in a size-dependent manner

@en

P1433

Q36016318-A1B930C1-C1EF-4A14-8DC1-D203FB7C3D39

P1476

Q36016318-0C994FE7-ECEC-4101-A211-FC0A97858E31

P2093

Q36016318-0BBF465F-891E-4C00-956D-82B84B9C1220

Q36016318-0DF58759-7A43-4B11-B027-E24DA385E46F

Q36016318-6151F505-DDBB-4093-9F55-AF8005F8B528

Q36016318-6453F666-BF7B-435F-AD61-53ECF33AD493

Q36016318-81036199-CFC7-457C-9D0D-267FF0D3C323

Q36016318-A536B83D-BD34-4D0C-B5C2-0FAA58339514

Q36016318-B31C1F22-4CDC-440F-9EEF-4D57865B9F6B

P2860

Q36016318-0CD1EA71-CBD7-4481-B803-100F29A26E51

Q36016318-0F1816D1-B7E5-42B1-8DB7-7A16CD147B3F

Q36016318-1986D632-C850-401C-BC5A-F7A45D3CD11A

Q36016318-2ABBC72D-D96E-498C-9EF6-F34B1EAC1AD8

Q36016318-2E19A8FE-CD54-44F2-894D-85DDD6E3B49F

Q36016318-34D3EFC2-3844-4357-BF52-9C01D67FEC2A

Q36016318-42948DD5-D0C7-49A5-925F-5DF802370051

Q36016318-534AE8EF-B425-4568-A3CA-E087F35ABFE0

Q36016318-58A331F8-5F88-45AD-B982-290A368DCA6A

Q36016318-5F6B6DA8-AECD-4C7B-A5C5-4F3B5DB4AA84

P2888

Q36016318-49C9C3AD-168D-4F1E-9902-833D32E34776

P304

Q36016318-6F1C67DC-2890-4B63-AB15-7A94D38C1214

P31

Q36016318-2BB33FBC-760E-49A2-8EBF-B9BFD119CA60

P356

Q36016318-72D1CF83-3188-47C4-89D8-8035FA788610

P407

Q36016318-F150BE72-3579-477E-AF3C-2C3C9827F005

P433

Q36016318-D3641711-0FCB-4420-A219-C2F1973732B6

P478

Q36016318-244A6B44-F83B-4802-B1BE-3E19D4245793

P50

Q36016318-476231A3-F465-4FFD-907A-3DB3978EA446

Q36016318-5B8CC6A1-C36A-4965-B7F7-8E0D9AADDA35

P577

Q36016318-8D5F1208-6660-4FE2-81CB-989CBAD07238

P5875

Q36016318-9B2B677D-7460-4E23-8D86-CFB73675AEEC

P698

Q36016318-6D83387C-1CD0-41E5-9A1C-D4C9DD2B13AF

P932

Q36016318-B9DDF872-46CB-4BF0-94A3-9F427FED56C2

P356

P1433

Nature Nanotechnology

P1476

Normalization of tumour blood ...... nes in a size-dependent manner

@en

P2093

Dai Fukumura

http://www.w3.org/2001/XMLSchema#string

John D Martin

http://www.w3.org/2001/XMLSchema#string

Ou Chen

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Vikash P Chauhan

http://www.w3.org/2001/XMLSchema#string

Walid S Kamoun

http://www.w3.org/2001/XMLSchema#string

Zoran Popović

http://www.w3.org/2001/XMLSchema#string

P2860

Why are tumour blood vessels abnormal and why is it important to know?

Openings between defective endothelial cells explain tumor vessel leakiness

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

Molecular mechanisms and clinical applications of angiogenesis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Nanocarriers as an emerging platform for cancer therapy

Normalization of the vasculature for treatment of cancer and other diseases.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Targeting of drugs and nanoparticles to tumors.

Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability

P2888

P304

383-388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NNANO.2012.45

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Triantafyllos Stylianopoulos

P577

2012-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223966336

http://www.w3.org/2001/XMLSchema#string

P698

22484912

http://www.w3.org/2001/XMLSchema#string

P932

3370066

http://www.w3.org/2001/XMLSchema#string